治験一覧
8,963 件中 3421〜3440 件を表示
日本人健康成人男性を対象としたTAK-123の静脈内投与後の薬物動態（PK）、安全性および忍容性を評価する試験
The purpose of this study is to evaluate the PK, safety and tolerability of phenylacetate and benzoate after intravenous administration of TAK-123 in Japanese healthy adult male participants.
過体重または肥満に苦しむ人々に対するNNC0174-0833の有効性を調査する研究。
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either take NNC0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take one injection once a week or once a day, depending on the treatment. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 8 months. Participants will have 12 clinic visits with the study doctor.
アトピー性湿疹患者を対象にBI 655130の効果と忍容性を検証する研究
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
軟骨無形成症の小児の臨床的および人体計測学的特徴を調査する観察研究。
This is a registry study in children with achondroplasia, age 0-10 years, to be conducted at multiple clinical centers in several countries. Information collected will include in anthropometric characteristics, related symptoms, tests, \& treatments Children's information will be collected in the registry for a maximum of 5 years.
転移性扁平上皮非小細胞肺癌（NSCLC、MK-7339-008/KEYLYNK-008）の一次治療におけるペムブロリズマブ（MK-3475）と維持療法としてのオラパリブの併用または非併用試験
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR). 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to overall survival (OS). As of Amendment 07, there will be no further analyses for OS and patient-reported outcome assessments.
ADPKD患者におけるバルドキソロンメチルの試験 - FALCON
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.
切除可能非小細胞肺癌患者に対する術前・術後デュルバルマブ療法の研究
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
日本人を対象としたClareon® IOL AutonoMe™の市販後臨床調査
This purpose of this survey study is to collect and describe clinical outcomes for the intraocular lens (IOL) delivery performance of Clareon® IOL AutonoMe™ when used in daily practice.
CSU患者を対象としたLOU064の長期安全性および忍容性を評価するための非盲検延長試験
The main objective to assess the long-term safety and tolerability of LOU064 in patients with chronic spontaneous urticaria (CSU) who have participated in study CLOU064A2201 (NCT03926611)
アトピー性皮膚炎の青年におけるJAK1阻害剤と外用薬併用療法
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.
プレセデックス特別検査（小児患者対象）
Secondary Data Collection:To confirm the safety and effectiveness profiles under the actual medical practice of Precedex in Japan.
アトピー性皮膚炎の小児および青年におけるバリシチニブ（LY3009104）の研究
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
C3GまたはIC-MPGNにおけるイプタコパンの長期的有効性、安全性および忍容性
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis
標準治療の適用が困難な真性多血症患者におけるP1101の有効性と安全性
This is a Phase 2 single arm study to investigate efficacy and safety of P1101 for adult Japanese patients with PV.
EGPA におけるメポリズマブと比較したベンラリズマブの有効性と安全性。
本試験は、安定した免疫抑制療法の有無にかかわらず、コルチコステロイド療法を受けている再発性または難治性EGPA患者を対象に、ベンラリズマブ30mgを皮下注射で投与した場合とメポリズマブ300mgを皮下注射で投与した場合の有効性および安全性を比較する、無作為化二重盲検実薬対照並行群間比較多施設共同52週間の第III相試験です。 IP投与による52週間の二重盲検治療期間を完了したすべての患者は、オープンラベル延長期間（OLE期間）への継続投与を受けることができます。OLE期間は、各患者がオープンラベルでベンラリズマブ30mgを皮下注射で投与し、少なくとも1年間治療を受けられるようにすることを目的としています（したがって、早期に登録された患者は1年を超えてOLE期間を継続することができます）。
H1-抗ヒスタミン薬でコントロール不十分な日本人CSU患者を対象としたリゲリズマブの安全性および有効性試験
The purpose of this study was to evaluate the safety and efficacy of ligelizumab in adult Japanese subjects with CSU, who remain symptomatic despite treatment with H1-antihistamines (AHs) at locally approved doses. The study population consisted of 66 male and female subjects aged ≥ 18 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-AH. This was a Phase III multi-center, open-label, single arm study. There was a screening period of up to 28 days, a 52 week treatment period, and a 12 week post-treatment follow-up period.
大腸がん（CRC）を含む進行固形腫瘍患者を対象としたE7386の試験
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
シスプラチン適応筋層浸潤性膀胱癌（MIBC）に対するペムブロリズマブ（MK-3475）と術前化学療法の併用とプラセボと術前化学療法の併用との比較（MK-3475-866/KEYNOTE-866）
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
進行固形悪性腫瘍患者を対象としたイフィナタマブ デルクステカン（DS-7300a、I-DXd）の試験
This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of ifinatamab deruxtecan (I-DXd). * Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of I-DXd when administered as a single agent. This study is expected to last approximately 5 years from the time the first participant is enrolled to the time the last participant is off the study. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: * they withdraw * their disease gets worse * they experience unacceptable side effects.
健康な被験者におけるMCI-186の治療用量および治療用量を超える用量でのQT間隔（QT）/補正QT間隔（QTc）に対する影響を評価する研究
To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)